Companies › Advenchen Laboratories Nanjing
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AL8326 | – | Phase 3 | Small Cell Lung Carcinoma | Jul 2028 |
| AL58805 | – | Phase 1 | Advanced Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07179081 | AL58805 | Phase 1 | Advanced Tumors | Oncology | Jan 2026 |
| NCT06247605 | AL8326 | Phase 3 | Small Cell Lung Carcinoma | Oncology | Jul 2028 |
No annotated target.
–
Advenchen Laboratories OSE Immunotherapeutics Clarity Pharmaceuticals TYK Medicines Impact Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.